Med Spa Business Plan: How to Write One in 2026

The sections a lender, a landlord and a medical director will actually test, with the 2026 numbers behind each one.

The average US med spa brought in $1,398,833 in a year, and 18% of the 10,488 med spas counted in AmSpa's latest industry report had opened that same year - AmSpa. That pace of openings is why so many founders are writing a med spa business plan right now, and it is also the problem. The market those openings were planned for has changed underneath them.

New patients made up 55% of aesthetic patients in 2021 and only 41% in the twelve months to March 2026, according to transaction data Guidepoint Qsight presented at RealSelf's 2026 summit - Qsight. Non-surgical patient spending was $10.5 billion in the first half of 2026 against $10.4 billion a year earlier, essentially flat - Qsight. A plan that assumes the boom years will repeat is a plan a lender should decline, and increasingly they do.

Here is the deeper problem: most med spa business plan templates are salon plans with Botox added. They ask for a mission statement, a competitor list and a five-year revenue line, and they skip the four things that actually decide whether a med spa survives: who is legally allowed to own it, who is allowed to treat which patient under whose supervision, what one unit of neurotoxin really earns after product cost, and how long the cash lasts while provider schedules fill.

This guide walks through every section of a med spa business plan in the order a lender reads it. It covers the ownership and supervision structure your state allows, how to size demand in your own trade area with free federal data, a scored launch menu of treatments, a sourced startup budget, the SBA rules that now govern most bank loans, staffing and pay, marketing that survives the FTC's review rules, the HIPAA-ready systems a med spa needs, and a worked three-year financial model you can rebuild with your own numbers. If you run a hair, nail or barber business rather than a medical practice, our salon business plan template is the better starting point; everything below is specific to medical aesthetics.

Contents

1. What a med spa business plan has to prove
2. Ownership, supervision and the legal structure
3. Market analysis: sizing demand in your trade area
4. The service menu and revenue model
5. Startup costs and the funding request
6. Staffing, pay and the medical director
7. Marketing and patient acquisition
8. Operations, software and where AI fits
9. Financial projections: a worked three-year example
10. Risks and how the plan answers them
11. Where med spas are heading, 2026 to 2028
12. Putting the plan together

At a glance: which treatments to open with

The single most consequential decision in a med spa plan is the launch menu, because it sets your capital needs, your staffing, your legal exposure and your margin all at once. Before the detail, here is how the five service lines most med spas consider compare on the evidence available in 2026. Each cell carries its score and the fact behind it, and the table is sorted by the weighted result.

How the criteria were chosen. Demand momentum (30%) uses Guidepoint Qsight's share of non-surgical patient spending in 2021 against the twelve months to March 2026, plus the latest quarterly change, because a plan has to ride demand that is growing rather than shrinking. Revenue per visit (20%) uses the American Society of Plastic Surgeons' published average fees and, for skin treatments, the spa industry's average revenue per visit, because a provider hour is the scarcest thing you sell. Capital to launch (20%) scores how much money has to be committed before the first patient, and clinical and regulatory risk (30%) scores how much can go wrong legally and medically. Where no reliable figure exists the cell shows a dash and the final score is weighted over the remaining criteria. Every number in the table is sourced in the sections below.

The ranking is not a recommendation to open with neurotoxins alone. The worked model in section 9 shows that an injectables-only menu struggles to clear a lender's coverage test, because product cost eats 38 to 50 cents of every injectable dollar, while a leased device line roughly doubles year-three margin despite scoring lower here on capital. The table tells you where the risk sits; the model tells you where the margin sits. A good plan uses both.

1. What a med spa business plan has to prove

A business plan is a sales document with an audience, and the audience for a med spa plan is unusually wide. The U.S. Small Business Administration says lenders and investors "commonly request" a traditional plan and that it "can be dozens of pages long" - SBA. Its Lender Match checklist is blunter: most lenders expect a business plan when you apply for startup funding - SBA Lender Match. But a med spa plan is also read by the landlord deciding whether to build out a clinical suite, by the physician weighing whether to put a license behind your protocols, and by the injector you are trying to hire away from a competitor.

Each of those readers is testing a different risk, and that is why a med spa plan cannot be a salon plan with a longer price list. The landlord wants to know you can carry a lease for ten years. The physician wants to know the structure will not expose their license. The injector wants to know there will be patients. The lender wants all three answered, plus proof the cash covers the debt. A plan that answers only the lender's question tends to fail the others, and a med spa needs all of them to say yes before it can open.

The sections the SBA expects

The SBA's traditional format lists eight sections: executive summary, company description, market analysis, organization and management, service or product line, marketing and sales, funding request and financial projections - SBA. It asks for a five-year financial outlook with monthly or quarterly detail in the first year, and it names the break-even analysis as "usually a requirement" for debt or investors. A lean plan, by contrast, fits on one page and can take "as little as one hour," which makes it a good working draft but rarely enough for a bank.

Read the right-hand column as the gap between a template and a fundable plan. Every row contains at least one element a general template never asks about: the supervision chain, fee-splitting, provider minutes per treatment, product cost per unit, a before-and-after photo policy. Those are the questions a medical lender or an experienced landlord will raise in the first meeting, so answering them in writing before they ask is the fastest way to look like an operator rather than an enthusiast.

Three questions every reader asks

Strip the sections away and every reader is asking three questions. Is it legal? That means ownership, supervision and scope of practice in your specific state, which section 2 covers. Will patients come? That means demand evidence from your trade area rather than national market-size headlines, which sections 3, 4 and 7 cover. Will the cash last? That means a month-by-month model that survives a slower ramp than you hope for, which sections 5 and 9 cover.

It helps to see what the polished competition looks like. LivePlan's sample plan for a five-room Sherman Oaks med spa asks for $1,050,000, funded by an $820,000 SBA 7(a) loan and $230,000 of owner equity, uses a management services organization with a professional corporation, and targets cash-flow break-even about twelve months after opening - LivePlan. Notice that the owner is putting in about 22% of the project, more than double the 10% minimum discussed in section 5. Section 9 shows why that is not an accident.

2. Ownership, supervision and the legal structure

This is the section templates skip and lawyers bill for, and it decides whether your plan can be executed at all. A med spa delivers medical treatments in a retail setting, and medicine is regulated state by state. Three bodies of rules shape the structure: the corporate practice of medicine, the rules on who may examine and treat a patient, and the rules on how money may flow between owners, physicians and staff. Get any of the three wrong and the plan fails on paper before it fails in practice. Nothing in this section is legal advice; it is a map of the questions your healthcare attorney needs to answer for your state.

The reason this matters more every year is that states are actively rewriting the rules. Texas restructured its med spa delegation rules in January 2025 and passed a separate IV therapy law the same year, California codified its corporate-practice restrictions for 2026, Rhode Island created a licensing regime for med spas, and Indiana now requires registration by January 2027. A plan written from a 2023 blog post can describe a structure that is no longer allowed.

The corporate practice of medicine

The corporate practice of medicine doctrine "restricts who can own practices, employ physicians, and receive payment for medical treatments," and a management services organization (MSO) "offers a legal pathway for non-physicians" - AmSpa. How strict the doctrine is depends entirely on the state.

California is the strictest common example. The Medical Board of California states that to offer laser and other cosmetic medical services, "the business must be a physician-owned medical practice or professional medical corporation with a physician being the majority shareholder," and that a physician working for a lay-owned business would be "aiding and abetting the unlicensed practice of medicine" - Medical Board of California. Its older guidance adds that management companies which control medical records, clinical hiring, coding and billing, or the selection of drugs and equipment "violate the law" - MBC. California's SB 351, signed in October 2025, took effect on January 1, 2026 and put several of those restrictions into statute, with enforcement by the Attorney General - Sidley Austin.

New York is similarly strict. The state education department says business corporations "cannot hire a licensee to provide professional services," that all shareholders of a professional corporation must be licensees of one profession, and that practicing a licensed profession without a license is a felony - NYSED. Health lawyers read this to mean a New York med spa entity must be wholly owned by licensed physicians - O'Connell and Aronowitz.

Florida regulates through facility licensing instead. Its health care clinic statute defines a clinic broadly and exempts entities wholly owned by licensed practitioners only where a practitioner-owner supervises the business and is legally responsible for compliance - Florida Statutes 400.9905. The practical lesson is the same everywhere: before you write a word of the financial plan, find out whether you, personally, are allowed to own the medical side of the business you are planning.

The MSO and professional corporation structure

Where the doctrine bars a non-physician from owning a medical practice, the usual answer is to split the business in two. A professional corporation owned by a licensed physician holds the medical practice: patient relationships, medical records and clinical decisions. A management services organization owned by the founder holds everything non-clinical (the lease, equipment, staff who do not practice medicine, brand and software) and charges the practice a management fee under a written services agreement. The diagram below shows the shape most attorneys start from.

Two details in the diagram carry most of the legal risk. The management fee has to reflect fair market value for real services rather than a share of medical profits, and the MSO must stay on the non-clinical side of the dashed line. California's guidance is explicit that an MSO controlling records, clinical hiring or drug selection crosses that line. Your plan should name the structure, the fee basis and the attorney who drafted the agreements, because a lender reading "MSO" without those details will assume the risk has not been handled.

Medical directors, good faith exams and delegation

The second set of rules governs who may assess a patient and who may treat them. AmSpa's guidance is that "only an MD, DO, NP, or PA can legally perform these assessments" (the good faith exam that establishes a patient relationship before a prescription treatment) and that an RN who performs one risks prosecution for practicing medicine without a license - AmSpa. California's board puts it in state-specific terms: physicians may direct registered nurses or physician assistants to inject Botox under supervision, "no unlicensed persons, such as medical assistants, may inject Botox," and the prior examination "may not be delegated to registered nurses" - Medical Board of California.

Texas spells out the sequence. Since January 9, 2025, before a delegated procedure a physician (or a PA or APRN acting under delegation) must establish a practitioner-patient relationship, keep an adequate record, disclose who will perform the treatment, and ensure someone trained in basic life support is present; the supervising provider must be on site or immediately available - 22 Texas Administrative Code 169.26. Practices must also post the names of delegating physicians and staff must wear name tags showing their credential - AmSpa.

Recent legislation shows the direction of travel, and your plan should state which of these apply to you:

• Texas HB 3749 ("Jenifer's Law") sets rules for elective IV therapy from September 1, 2025, limiting who may order and administer it - Texas Legislature
• Rhode Island now requires med spa medical directors to be physicians or certified nurse practitioners with cosmetic training - Nixon Peabody
• Indiana SB 282 takes effect July 1, 2026, requires a responsible practitioner and adverse-event reporting, and requires registration by January 1, 2027 - AmSpa
• Arizona revised its nursing board's aesthetics opinion in January 2025 into three procedure levels, and Illinois guidance bars estheticians from Botox and chemical peels even when delegated - Mintz

The pattern across these changes is consistent: states are tightening who may supervise, who may treat, and how incidents are reported, usually after a patient was harmed. For a business plan, that means two practical things. First, your supervision costs (medical director time, on-site requirements, additional prescribers) should be budgeted at the level your state requires today plus a margin for tightening. Second, any service line that depends on a loose interpretation of scope of practice, such as IV hydration run by staff without on-site oversight, belongs in the risk section rather than the revenue forecast.

How money may flow

The third rule is the one most likely to surprise a founder from the salon world. Commission pay is the default in hair and nails, but AmSpa has warned that "in most states, if medical spa owners are paying employees commission, they are engaging in an illegal practice known as fee-splitting" - AmSpa. Medical directors must be paid fair market value for their actual work, "not paying for the use of the physician's license, which is prohibited in every state" - AmSpa. Your compensation plan in section 6 has to be designed around those two sentences.

AmSpa's legal webinar series is the most practical way to hear how these rules play out in real cases. In this May 2026 session, healthcare attorneys walk through oversight duties and the legal precedents that now shape supervision and liability.

The structure you choose flows into every later section. It sets who signs the lease, who employs the injectors, how the management fee appears in the projections, and which entity borrows. Write it down in plain language in the company description, name the attorney, and attach the state rules you relied on. A lender cannot evaluate a med spa without knowing which entity earns the medical revenue, and a physician will not join one that cannot say.

3. Market analysis: sizing demand in your trade area

The market analysis is where most med spa plans quote a national market-size figure and move on. That is the weakest possible evidence, because a lender is not lending against the US market; it is lending against one location's ability to fill appointment slots within a short drive. The national picture still matters for one reason: it tells you whether you are entering a growing category or a maturing one, and in 2026 the honest answer is that med spas are maturing.

The industry grew fast for a decade. Baird's recap of the 2025 Medical Spa Show notes the industry "expanded more than sixfold from about 1,600 locations to more than 10,000" between 2010 and 2023 - Baird. AmSpa counted 5,431 med spas in 2018 and 7,430 in 2021 - AmSpa. Its most recent report puts the count at 8,899 in 2022 and 10,488 in 2023 - AmSpa.

Read the chart as supply, not demand. Nearly doubling the number of locations in five years means the average spa now competes with far more neighbors for the same patients. The demand side has flattened at the same time: same-store growth at med spas "dipped below 1%" in 2025, according to a Qsight and Skytale study reported by Beauty Independent - Beauty Independent. Zenoti's platform data shows new-client visits at med spas fell 11% in 2025 - Zenoti. More spas chasing flat demand is exactly the condition in which a location-level plan matters more than a national one.

What the average med spa looks like

AmSpa's industry summary is still the most useful benchmark set, because it describes the business you are actually building rather than the aesthetics market as a whole. The graphic below is AmSpa's own summary of its 2024 report.

The figures worth carrying into your plan are the operating ones. The average med spa saw 245 patient visits a month, patients spent an average of $527 per visit, 73% of patients were repeat patients, 81% of med spas operate a single location, and single-location practices average eight employees - AmSpa. The same report found 89% of patients are women, that 67% of single-owner practices are owned by people who are not physicians or surgeons, and that only 3% of med spas are owned by private equity. Those numbers give you sanity checks: if your plan shows 600 visits a month in year one with four employees, a reader will notice.

Treat national market-size estimates with care, because they measure different things. AmSpa describes a $17 billion industry - AmSpa. Precedence Research sizes the US med spa market at $7.43 billion in 2025 - Precedence Research. Qsight's transaction data, which counts med spas and physician offices together, recorded $10.5 billion of non-surgical patient spending in the first half of 2026 alone - Qsight. None of them is wrong; they draw the boundary differently. Pick one, say which boundary it uses, and do not let it carry any weight in your revenue forecast.

Sizing your own trade area with free data

The evidence a lender respects is local, and most of it is free. Start by understanding that there is no NAICS industry code for "medical spa"; the federal classification files place day spas and laser hair removal under 812199 (Other Personal Care Services), estheticians under 812112 (Beauty Salons), and dermatology and plastic surgery offices under 621111 - U.S. Census Bureau NAICS 2022. Competitor counts therefore have to be assembled from several codes plus your own search of the map.

That assembly is worth the effort because it answers the question a landlord and a lender will both ask: how many people within a short drive could plausibly become patients, and how many providers already compete for them? A competitor map that shows every med spa, dermatology office and plastic surgery practice inside your radius, each with its posted price per unit and its review count, is more persuasive than any industry statistic. The federal data gives you the denominator (households, income, existing establishments), and your own map gives you the competitive set.

Four federal sources do most of the work:

• County Business Patterns reports establishments by industry and county, with ZIP-level establishment counts; the most current release covers 2023 - Census CBP
• Nonemployer Statistics counts businesses with no paid employees, which is where solo injectors and estheticians appear; the 2024 data was released September 29, 2026 - Census
• American Community Survey 5-year estimates give median household income down to ZIP code tabulation areas; the 2020-2024 release came out January 29, 2026 - Census
• Census Business Builder combines these into maps by location and business type without any coding - Census Business Builder

Two cautions keep this research honest. County Business Patterns excludes self-employed individuals and, at ZIP level, publishes only establishment counts for detailed industries rather than employment or payroll - Census methodology, so a ZIP with "three" beauty establishments may hide a dozen solo practitioners that only the nonemployer data reveals. And Google Trends is not search volume: it shows a sample of searches, each point divided by total searches in the area, scaled from 0 to 100 - Google. Use it to compare interest in "Botox" against "Dysport" or one city against another, never to estimate how many people will book.

The output of this research should be a one-page trade-area profile: the drive-time radius you serve, households and median income inside it, every competing med spa, dermatology and plastic surgery office you found with their posted neurotoxin price per unit, and an estimate of how many treatments your area can absorb. That last number comes from bottom-up arithmetic (adults in your target age band, a plausible treatment rate, visits per year) rather than from a national report, and stating your assumptions openly is more persuasive than any market-size citation.

Who your patients will be

The patient base is shifting younger, though it is still overwhelmingly female. AAFPRS reported in February 2026 that 57% of facial plastic surgeons saw more patients under 30 requesting procedures or injectables - AAFPRS. Qsight found Gen Z now accounts for more than 10% of aesthetic patients, with lower retention (45% against 54%) and lower spend per visit ($384 against $524) than older patients - Qsight. A consumer survey by the American Society for Dermatologic Surgery found 70% of respondents were considering a cosmetic procedure, with cost the top barrier - ASDS.

For the plan, the implication is a two-speed patient model. Younger patients are a growing acquisition channel but a weaker retention base, so a plan that leans on them needs a stronger rebooking and membership engine than one built on the 35-to-54 core that AmSpa describes. Write down which segment you are building for first, why your location suits it, and how your pricing and menu reflect it. The rest of the plan, from the menu to the marketing budget, should follow from that choice.

4. The service menu and revenue model

The service line section is where a med spa plan either becomes credible or falls apart, because it is where the economics live. Every treatment has a price, a product cost, a provider time, a repeat cycle and a legal profile, and the combination of those five numbers across your menu is your business model. The national spending mix is the best starting point for thinking about it, because it shows where patient money actually goes.

Guidepoint Qsight's transaction data covers non-surgical spending at med spas and physician offices together. Comparing 2021 with the twelve months to March 2026 shows the shifts that matter for a 2026 plan: neurotoxins growing their share, fillers shrinking, and weight loss appearing almost from nothing.

Two readings of this chart change how you build a menu. Neurotoxins are the anchor because they are both the largest category and the most repeatable, and Qsight reports neurotoxin patient spending reached nearly $1.8 billion in Q2 2026, up 9% year over year - Qsight. And the categories that grew fastest are not necessarily the ones to build around: weight loss jumped to 11% of spending but fell 22% year over year in Q1 2026, while fillers declined for two years before Evolus reported the hyaluronic acid category "returning to positive growth" in mid-2026 - Evolus.

Neurotoxins: the anchor line

Neurotoxins anchor most med spa plans because the product dictates the repeat cycle. The Botox Cosmetic label states that the effect lasts "approximately 3-4 months" and that dosing more often than every three months has not been evaluated, with standard doses of 20 units for frown lines and 64 units when frown lines, crow's feet and forehead lines are treated together - AbbVie prescribing information. A patient who likes the result returns three or four times a year, which is why neurotoxin patients are the foundation of every retention metric in the plan.

The margin is thinner than founders expect. Allergan's published wholesale acquisition cost for Botox Cosmetic is $656 for a 100-unit vial, or $6.56 per unit before any rebates - Allergan Aesthetics. ASPS reports an average neurotoxin treatment fee of $435 - ASPS. Industry consultant Bryan Durocher puts product cost for toxins and fillers at "anywhere from 38 to 50 cents on the dollar" - Beauty Independent. Loyalty pricing narrows that range: Allergan's practice program added a quarterly rebate on eligible Botox Cosmetic purchases in August 2026 - PR Newswire.

Brand choice is a pricing decision as much as a clinical one. AbbVie's own annual report says US Botox Cosmetic revenue fell 11% in 2025, "primarily driven by unfavorable pricing due to customer loyalty program changes, lower market share and decreased consumer demand" - AbbVie 10-K. Over the same year, Evolus grew Jeuveau-led revenue 12% to $297.2 million in 2025 - Evolus. Patients ask for brands by name, and manufacturers compete on price and loyalty programs, so the plan should state which brands you will carry, what you will pay per unit after rebates, and what you will charge.

Fillers, devices and skin treatments

Fillers earn more per visit but carry more risk. ASPS reports an average fee of $715 for hyaluronic acid filler - ASPS, and the category's product cost sits in the same 38-to-50-cent range as toxins. The clinical stakes are higher (vascular complications are the reason filler training matters), and the legal record is unforgiving, as section 10 shows. Most plans offer fillers from launch only when the founding injector already has filler experience and a complication protocol.

Energy-based devices are the opposite trade: low cost per treatment, heavy fixed cost. Equipment lenders put laser platforms at $80K to $250K, RF microneedling at $40K to $120K and IPL at $25K to $80K, and one lender's worked example finances a $130K device with 10% down over 60 months at about $2,486 a month - Axiant Partners. ASPS reports an average fee of $697 for laser skin treatments such as laser hair removal - ASPS. The arithmetic every plan should show is simple: divide the monthly device payment by the contribution per session (price minus consumables and provider time) to get the sessions per month needed to cover the device, then compare that with realistic demand.

Medical-grade skin treatments (peels, medical facials, skincare protocols) are the low-risk, low-ticket line. A spa visit averaged $123.10 in 2025, far below injectables, but these treatments bring patients in between injectable cycles and give estheticians productive hours. Check your state's scope rules before writing them into the plan: Illinois guidance bars estheticians from chemical peels even when a physician delegates them, as noted in section 2.

GLP-1 and IV programs: revenue you should not lean on

Weight-loss programs became a major revenue line in two years. Qsight reported that 60% of US med spas were selling GLP-1 medications in early 2025 - Qsight. A later industry survey put the figure at 54% by August 2025 - ReachMD. But the regulatory ground moved underneath them. The FDA declared the semaglutide shortage resolved and ended the grace periods for compounding pharmacies and outsourcing facilities on April 22 and May 22, 2025 - FDA. In April 2026 it proposed excluding semaglutide, tirzepatide and liraglutide from the list outsourcing facilities may compound from in bulk - FDA.

The commercial data has followed. Weight-loss spending at aesthetic practices fell 22% in Q1 2026, and fewer than 20% of patients who started a GLP-1 program returned for a non-weight-loss purchase - Qsight. In a business plan, that combination argues for treating weight loss as an optional add-on with its own risk paragraph rather than a pillar of the forecast. Elective IV therapy deserves the same treatment for a different reason: Texas wrote a dedicated law for it after a patient death, and other states are watching.

Memberships and loyalty programs

Memberships turn a three-or-four-visit neurotoxin habit into predictable monthly revenue, and they are the strongest retention tool in the plan. AmSpa's industry data has long shown majority adoption, with 55% of med spas running some kind of membership program as of its 2017 report - AmSpa. One practice's results, reported by AmSpa, showed members visiting 2.9 times a year against an industry average of 1.44 and spending 35% more - AmSpa. More recently, Zenoti's platform data shows med spa membership sales grew 13% in 2025 even as new-client visits fell - Zenoti.

Manufacturer loyalty programs run alongside your own. AbbVie says its Allē program has eight million members earning points across more than 50 products and treatments at 30,000 US practices - AbbVie. Your plan should explain how a membership is priced (a monthly fee that banks toward treatments, or a discount club), what it costs you in discount, and how you will measure whether members actually return more often. The rebooking mechanics behind that, from pre-booking at checkout to win-back messages, are covered in our guide to rebooking and retention.

5. Startup costs and the funding request

Startup cost is the number founders search for first and the number published sources agree on least, because "a med spa" can mean a single treatment room inside a dermatology office or a five-room flagship with three lasers. The honest way to present it in a plan is as a ranges table from named sources, followed by your own line-by-line budget built from quotes. A lender does not need you to match an industry average; it needs every line in your budget to be traceable to a quote, a lease or a published rate.

The published ranges are wide for real reasons. Vagaro estimates $200,000 to $350,000 for a small one-to-two-room med spa, $350,000 to $500,000 for three to four rooms, and $500,000 to $1,000,000 or more for a premium location, with $75,000 to $200,000 to add aesthetics to an existing practice - Vagaro. The International Association for Physicians in Aesthetic Medicine gives $100,000 to $500,000, with build-out alone at $150 to $300 per square foot - IAPAM. A healthcare construction firm puts California medical tenant build-outs at $150 to $350 per square foot with 12 to 24 or more weeks of construction - The Barrie Company. Note that the vendor and lender estimates come from companies that sell to med spas, so treat them as ranges to test rather than facts.

A startup budget built from sources

The biggest swing factor is the space. Building a clinical suite from a bare shell at $150 to $300 per square foot puts a 1,200-square-foot space at $180,000 to $360,000 before a single device, which is why many first-time owners lease a second-generation clinical space that needs finishing rather than construction. The worked budget below assumes that route, leases rather than buys its one device, and carries a large working capital reserve because, as section 9 shows, the cash low point arrives well after opening day.

The working capital line will surprise anyone who has opened a salon, and it is the line lenders scrutinize most. It is large because a med spa carries clinical payroll from the first month while provider schedules fill over a year or more. If your own model produces a much smaller reserve, check whether you have assumed a faster ramp than the evidence in section 9 supports. Running out of cash at month fourteen with a full schedule in sight is the most avoidable way to lose a med spa.

SBA 7(a) loans and the rules that changed on October 1, 2026

Most bank financing for a new med spa runs through the SBA's 7(a) program. Its maximum loan amount is $5 million, and eligible uses include working capital, equipment, furniture and fixtures, and real estate - SBA. Equipment and working capital loans run ten years or less, real estate up to 25 years, and the SBA guarantees up to 85% of loans of $150,000 or less and 75% above that - SBA terms. Variable rates are capped at the base rate plus 6.5 points for the smallest loans, falling to plus 3.0 points for loans over $350,000; with the prime rate at 7.00% as of September 16, 2026 - FedPrimeRate, the cap on a larger loan is about 10%.

The lending rulebook itself, SOP 50 10, moved to version 8.1 on October 1, 2026 - SBA. Four of its rules shape a med spa plan directly:

• Equity injection. A start-up (in operation one year or less) must inject at least 10% of total project costs, counting everything needed to become operational
• Debt service coverage. Standard 7(a) start-ups need projections showing coverage of at least 1.15 within two years of funding, plus an analysis of working capital adequacy over the next twelve months
• Personal guarantees. Anyone owning 20% or more must give an unlimited personal guaranty, and lenders take available equity in personal real estate when business collateral falls short
• Ownership eligibility. All owners and required guarantors must now be U.S. citizens or U.S. nationals; version 8.1 lists lawful permanent residents as ineligible

Those rules come from the SOP text itself - SBA SOP 50 10 8.1, and two of them change how you write the plan. The coverage test means your year-two projection is not a forecast for your own comfort; it is the number the lender underwrites, and section 9 shows how hard 1.15 is to reach for a new location. The ownership rule means a founding team that includes a green-card holder needs a different financing route or a different ownership split, a question to settle with counsel before the plan is written rather than after a lender declines it.

Other money: 504 loans, equipment finance and patient financing

The SBA 504 program lends up to $5.5 million for real estate and long-lived equipment but cannot fund working capital or inventory - SBA, so it suits owners buying a building more than tenants. Equipment lenders finance devices over 48 to 72 months, offer a choice between a $1 buyout and a fair-market-value lease that makes upgrades easier, and note that certified pre-owned devices can cut device cost by 30% to 50% - Axiant Partners. Leasing keeps cash in the working capital reserve, which matters more in year one than ownership of the asset.

Patient financing belongs in the plan as a revenue and cost line. CareCredit says it charges providers no annual or monthly fees, pays the practice within two business days and is non-recourse, with transaction fees depending on the promotional option - CareCredit. Cherry advertises merchant fees starting at 1.7% to 1.9% on plans up to $65,000 - Cherry. In an AmSpa member survey, 41% of respondents named high merchant fees as a hurdle - AmSpa. Model financing fees as a percentage of the treatments you expect to be financed, and treat any lift in ticket size as upside rather than base case.

6. Staffing, pay and the medical director

Payroll is the largest controllable cost in a med spa, and the staffing plan is where the legal structure from section 2 becomes a budget. The plan should show every role, when it is hired, what it costs fully loaded, and what license it carries, because the license determines what the person may do and therefore how much revenue they can produce. AmSpa found single-location practices average eight employees - AmSpa, a useful ceiling check for a first-year plan.

Salary benchmarks come from two sources that disagree in a useful way. AmSpa's 2024 summary lists average full-time salaries of $86,983 for RNs, $131,571 for nurse practitioners, $59,739 for estheticians and $135,258 for medical directors - AmSpa. Across all employers, the Bureau of Labor Statistics puts the May 2025 median for registered nurses at $97,550 - BLS. Nurse practitioners earn a median $132,300 - BLS. Receptionists working in healthcare earn a median $19.00 an hour - BLS. Skincare specialists earn a median $45,330, as our esthetician wage data shows. An aesthetic RN competing with hospital pay is the hire most likely to cost more than your plan assumes.

The table is a worked example, not a template. Many founders are themselves the lead injector and pay themselves less than market in year one, which improves the early cash position but must be shown honestly (a lender will add back a realistic salary when judging the business). The second clinician is the key timing decision: hire too early and payroll outruns revenue, hire too late and the lead injector's schedule caps growth. A useful trigger is utilization, since Zenoti reports the median med spa staff utilization is just 38% - Zenoti; a lead injector consistently booked well above that is the signal to add capacity.

Paying clinicians without fee-splitting

Pay design is where med spa plans most often import a salon habit that is illegal in medicine. As section 2 notes, AmSpa warns that commission pay for medical services is fee-splitting in most states. The safe default is salary or hourly pay, with any incentive structured by your healthcare attorney around measures your state permits, such as patient reviews, retail sales or rebooking rates. Write the structure into the plan, because an experienced lender or investor will ask how you avoid the problem.

Medical director pay needs the same care. Fees in the market vary widely: one medical director service quotes $800 to $2,500 a month plus $200 to $500 for each additional injector - Medical Director Co. IAPAM cites $1,500 to $5,000 a month - IAPAM. Whatever the number, AmSpa's rule applies: pay must reflect fair market value for real supervision, chart review and protocol work. Document the hours and duties in the agreement and in the plan, so the fee reads as a service rather than a license rental.

7. Marketing and patient acquisition

The marketing section of a med spa plan has to answer a harder question in 2026 than it did in 2021: where will new patients come from when there are fewer of them to go around? With new patients falling from 55% to 41% of the aesthetic patient base, the plan has to show two engines working together, one that wins first visits at a known cost and one that turns first visits into the repeat neurotoxin cycle. Most plans describe the first engine in detail and leave the second to chance.

Start with the cost of a new patient, because it converts a marketing budget into a patient count. A marketing agency's survey of practices, published on AmSpa's news site, reported an average cost of $39 per lead and $132 per new patient, with 70% of practices naming Instagram their most effective platform and only 7% using TikTok effectively - AmSpa. The figures come from a vendor without published methodology, so use them as a starting assumption and replace them with your own results within three months of opening.

Reviews decide the shortlist

Reviews are the conversion step between being found and being booked, and the thresholds patients apply are rising. BrightLocal's 2026 survey found 97% of consumers read reviews for local businesses, 31% will only use a business rated 4.5 stars or higher, 47% will not use one with fewer than 20 reviews, and 74% look for reviews written in the last three months - BrightLocal. For cosmetic procedures specifically, 94% of respondents in the ASDS survey said rating and review websites influence their decision - ASDS. A new spa therefore needs a review plan from week one, and our guide to getting more salon reviews walks through the asking and responding system in detail.

The same BrightLocal survey shows where discovery is moving: the share of consumers using generative AI tools for local recommendations rose from 6% to 45% in a year. Being the clinic an assistant recommends depends on the same signals as local search (a complete Google Business Profile, recent reviews, clear service pages), plus pages written so they can be quoted. Our guide to how clients find a beauty business in 2026 covers local search and AI answers channel by channel. For what makes a page citable by an AI assistant, see our entry on generative engine optimization.

The rules your marketing must follow

Med spa marketing operates under three overlapping rulebooks, and the plan should show you know them. The FTC's rule on fake reviews and testimonials, effective October 21, 2024, bans fake or AI-generated reviews, incentives conditioned on positive sentiment, undisclosed insider reviews and review suppression through threats - FTC. Knowing violations carry civil penalties of up to $53,088 per violation - Federal Register. The FTC's guidance allows incentives for reviews only when there is no requirement, express or implied, that the review be positive - FTC Q&A.

Before-and-after imagery carries its own risk. FTC guidance for health claims says a "results not typical" label is not enough without a clear disclosure of the results a typical consumer can expect - FTC. California's medical board has long prohibited using models without saying so, or touched-up photos, in medical advertising - MBC. If your practice is a HIPAA covered entity, using a patient's information for marketing generally requires their written authorization - HHS. Tracking pixels that send protected health information to advertising platforms are restricted - HHS.

Put together, the marketing plan should contain a launch budget, a monthly budget expressed as new patients at your assumed cost per patient, a review program, a written consent and photo policy, and a retention program measured by rebooking rate. The broader channel strategy for a small beauty business, from referrals to text reminders, is covered in our salon marketing guide; the med spa version adds the compliance layer above. Keep the budget tied to the patient math in section 9, so the marketing line and the revenue ramp are visibly the same assumption.

8. Operations, software and where AI fits

The operations plan is where a reader checks whether you understand the day-to-day of a medical practice that sells like a retailer. It should describe the path a patient takes from first inquiry to the next booking, the system that handles each step, and the controls that keep the practice compliant. That path is longer than a salon's, because a prescription treatment requires an exam, a consent and a clinical record before the product ever touches a patient.

Mapping the path also exposes where revenue leaks. Zenoti's 2024 platform data shows med spas had the highest no-show rate of any category at 5% and a 16% cancellation rate - Zenoti. Its 2026 benchmark found cancellations improving to 14% while patients who had rebooked only once cancelled 37% of those appointments, against 4% for patients rebooked two or more times - Zenoti. At a med spa ticket, those leaks add up fast: Zenoti's benchmark puts the average med spa's no-show loss at about $820 a week.

Every box in the diagram is a system decision. Booking with a deposit or card on file is the first defense against no-shows. PatientNow notes most med spas require at least 24 hours' notice to cancel and some require 48 for longer or costlier services - PatientNow. Our cancellation policy template gives you editable wording to adapt with your attorney. Intake and consent forms should be completed before arrival, and our client intake form shows the non-clinical structure a medical intake builds on. The chart must record product, units, lot numbers and treatment areas, because a recall or a complication investigation will ask for exactly that.

HIPAA: when it applies and what it requires

HIPAA applies to a health care provider "only if" it transmits health information electronically in connection with a transaction HHS has adopted a standard for, such as insurance billing - HHS. A strictly cash-pay med spa that never sends such transactions may fall outside the rule, but that is a narrow position to rely on, and patients, lenders and partners increasingly expect HIPAA-grade handling regardless. Where the rule does apply, any cloud vendor that stores or transmits patient health information on your behalf is a business associate and must sign a business associate agreement, even if it only stores encrypted data it cannot read - HHS.

Practices outside HIPAA are not outside regulation. HHS points non-covered businesses that collect consumer health information to the FTC Act and the FTC's Health Breach Notification Rule - HHS. Email to patients is permitted with safeguards, and when a patient emails first a provider may assume email is acceptable unless the patient says otherwise - HHS. The practical rule for the plan: choose systems that will sign a BAA, list which vendors touch patient data, and state who in the practice is responsible for privacy.

Choosing the practice software

Med spa platforms bundle booking, charting, consents, photos, memberships and payments, and their published prices and BAA terms vary more than their marketing suggests. The table below summarizes what each vendor publishes on its own site as of October 2026; quote-only vendors are marked as such.

Two patterns in the table matter for the plan. First, a BAA is often opt-in: Mangomint says HIPAA compliance is not enabled automatically and must be requested - Mangomint. Boulevard's BAA comes with its med spa add-on - Boulevard. Second, charting depth differs: lot-number tracking as structured data, as Zenoti describes - Zenoti, makes recalls and inventory reconciliation far easier than free-text notes. Our spa software guide compares these platforms in more depth. For head-to-head detail on two of the most common med spa choices, read Zenoti vs Boulevard. If you are weighing the lighter-weight options, the Boulevard vs Mangomint comparison covers them.

The image below, from Zenoti's own product pages, shows what structured injectable charting looks like in practice: treatment areas, units, lot numbers and photos captured in one record rather than typed into free text.

When you evaluate any platform, test the record itself rather than the demo script: chart a mock neurotoxin treatment with two products and two lot numbers, attach photos, collect a consent signature, and then pull a report of every patient treated from one lot. A system that cannot answer that last request quickly will cost you hours in a recall and credibility in an audit.

Where AI fits, and where it does not

AI is arriving in med spa software fast, mostly as front-desk and documentation tools. Boulevard prices its AI receptionist at $125 a month per location for 200 minutes plus $0.60 a minute beyond that - Boulevard. Its support center describes it as still in beta and rolling out gradually - Boulevard. Moxie, which raised a $25 million Series C in 2026, says its booking assistant will soon respond to inquiries and book appointments - AmSpa. Patients are open to it: in a Zenoti survey, 64% of med spa regulars said 24/7 receptionist access is extremely or very valuable - Zenoti.

The limits are as important as the features. Any AI tool that touches patient information is a vendor like any other, so the BAA requirement above applies to it, and an AmSpa analysis notes that for operators choosing AI vendors on their own, "the entire privacy and validation burden falls on the practice" - AmSpa. The FTC has also been explicit that "there is no AI exemption from the laws on the books," including in a case against an AI tool used to generate fake reviews - FTC. AI can answer the after-hours "how much is Botox" text and hold the slot with a card; it must never give clinical advice or decide who is a candidate for treatment.

The safest way to write AI into a plan is as short jobs with a checkable result: a missed call answered and booked, a reminder sent, a chart note drafted for the clinician to approve. Long unsupervised chains of tasks fail in ways that are hard to spot. SalonAI is built and run on Founden, a platform our founder also runs, and its guide to autonomous businesses lays out the failure data on AI agents running multi-step business workflows: error rates that compound with every added step, and ordinary chatbots rebranded as "agents." Our own overview of what AI actually does well for salons and spas applies the same test to front-desk, booking and marketing tools. The missed-call problem gets its own treatment in our guide to the AI front desk.

There are three ways to staff the non-clinical systems, and the plan should name the one you chose. You can run them yourself inside your practice platform, hire an agency for the website and marketing, or hand the whole non-clinical layer (website, booking pages, reminders, review requests, marketing and the owner's weekly numbers) to a service that builds and runs it; SalonAI is one option in that last group. Whichever route you pick, the boundary stays the same: patient charts live in a clinical system that signs a BAA, and nothing automated crosses into clinical judgment.

9. Financial projections: a worked three-year example

The financial section is where every earlier choice becomes a number, and where most plans either convince a lender or lose them. The SBA asks for a five-year outlook with monthly or quarterly detail in year one, income statements, balance sheets, cash flow statements and a capital budget - SBA. Rather than show a template, this section walks through a complete worked example built only from the sourced inputs in this guide, so you can see how the pieces interact and rebuild it with your own figures.

The example is a two-treatment-room med spa in a suburban US market with a nurse practitioner as lead injector, an esthetician, a patient coordinator and a medical director from opening, an RN added in month four to run a leased laser and take injection overflow, and the startup budget from section 5. It is deliberately ordinary: no celebrity injector, no existing patient list, no unusually cheap lease. That makes it a stress test rather than a pitch.

The assumptions

The visit ramp is the assumption to argue about, and it should be argued about in your plan too. The example reaches 260 visits a month by month 24, close to the AmSpa average of 245, and AmSpa's single-location average monthly revenue of $92,167 sits below the example's month-24 revenue of $105,425, so the ramp is ambitious rather than conservative. If your trade-area research in section 3 cannot support that pace, slow it down and watch what happens to the cash.

The result

The chart shows the same story month by month. Revenue crosses total costs in month 18, and the cumulative cash low point of -$326,773 arrives in month 17, which is why the working capital reserve in section 5 is so large.

Read the year-three margin of 13.3% against the benchmarks rather than against hope. A broker writing on AmSpa's site describes 20% net profit as the minimum for a sellable med spa and 30% to 35% for highly efficient ones, with blended product cost ideally between 20% and 30% - AmSpa. The example's product cost sits above that range at about 32% because it is injectables-heavy, which is exactly the lever the sensitivity table below isolates.

What moves the answer

A single forecast is a guess; a plan shows how the guess behaves when it is wrong. The table reruns the same model with one assumption changed at a time. The coverage column uses each scenario's own loan size, because a slower ramp needs a bigger working capital reserve and therefore a bigger loan.

Three lessons fall out of the table, and each belongs in your plan's narrative. Volume dominates everything: a 20% swing in visits moves break-even by a year and year-three margin by eighteen points, so the trade-area evidence and the acquisition plan are the real collateral. Product cost is the second lever: four points of injectable cost is worth three points of margin, which is why buying programs and brand choices belong in the plan. And the menu mix matters more than it looks: dropping the device line and its clinician lowers costs, yet still roughly halves year-three margin, because the device revenue carries almost no product cost.

Passing the lender's coverage test

The SBA's start-up rule asks for projected coverage of at least 1.15 within two years of funding. The base case reaches only 0.23 in year two, so as written it would not qualify, and that is the most useful thing the model can tell you before a lender does. Even the existing-book scenario, where the founding injector brings existing patients along and year-two EBITDA reaches $65,721, would support a loan of only about $360,000 at 1.15 coverage against a $588,000 project. The remaining $228,000, roughly 39%, would have to come from the owner rather than the 10% minimum.

That arithmetic explains the 22% equity in LivePlan's sample plan and the advice most experienced operators give: open smaller, lease rather than buy, start with a provider who already has a following, and bring more of your own money than the minimum. The break-even formula the SBA publishes (fixed costs divided by price minus variable costs) is the quick check for each decision - SBA; the model above is the full version. AmSpa's September 2026 session on reading a med spa P&L is a useful companion if you are building your first set of projections.

Once the base case, the sensitivities and the coverage test are on paper, the financial section writes itself: a monthly year-one table, annual years two to five, a sources and uses table, and a paragraph explaining which assumptions you are least sure of and what you will do if they miss. Lenders do not expect your forecast to be right. They expect you to know which parts of it could be wrong.

10. Risks and how the plan answers them

Every plan has a risk section, and most of them list generic risks ("competition," "economic downturn") with generic answers. A lender reads that as a sign the founder has not thought about what specifically goes wrong in a med spa. The risks below are the ones that actually close practices or drain them, each paired with the evidence and the operational answer your plan should give.

The common thread is that med spa risk is concentrated in a few predictable places: the product in the syringe, the documentation around the treatment, the rules that keep changing, and the people who hold patient relationships. A risk section that names those four and shows a control for each is more reassuring than any amount of optimism in the revenue forecast.

Product integrity and counterfeit toxin

Counterfeit and mishandled botulinum toxin is not hypothetical. In April 2024 the CDC reported 22 people in 11 jurisdictions who fell ill after injections given by unlicensed or untrained people or in non-healthcare settings, and recommended FDA-approved toxin from licensed providers, preferably in a licensed healthcare setting - CDC. The FDA's alert described counterfeit cartons labeled "Botulinum Toxin Type A" rather than the authentic "OnabotulinumtoxinA," showing a 150-unit dose that is not a size the manufacturer makes, and told providers to check every product for signs of counterfeiting - FDA.

The FDA kept enforcing in late 2025, sending warning letters to online sellers of unapproved toxin products such as "Botulax 200U" and warning that such drugs may be contaminated, counterfeit or contain varying amounts of active ingredient - FDA. The plan's answer is procedural: buy only from manufacturers or their authorized distributors, record the lot number of every vial in the chart, reconcile units used against units purchased each month, and say so in writing. That control also protects your margin, since unexplained unit losses are one of the first things an inventory reconciliation reveals.

Complications, consent and litigation

Litigation data from the last two years is sobering for med spas specifically. A 2026 study of every publicly indexed med spa malpractice case in Westlaw from 2006 to 2024 found 20 jury trials, plaintiffs winning 13, and an average jury award of $2,489,128.69 - Annals of Plastic Surgery. A separate 2026 review of 46 US filler lawsuits found med spa procedures had a 100% plaintiff verdict rate against 47% in private clinic or hospital settings, and that documented informed consent cut plaintiff verdict rates from 65% to 8% - Aesthetic Surgery Journal.

The pattern is older than the latest studies. A 2014 JAMA Dermatology analysis found the share of laser-injury lawsuits involving non-physician operators rose from 36.3% to 77.8% between 2008 and 2011 - JAMA Dermatology. A 2026 systematic review of 1,409 cases found 45% of claims favored plaintiffs, commonly driven by "procedural errors, inadequate informed consent, and incomplete documentation" - Dermatologic Surgery. The plan's answer is documentation and coverage: treatment-specific consent forms, photos before every treatment, written complication protocols reviewed by your medical director, training records for every injector, and professional liability insurance priced into the budget.

Regulatory change

Section 2 showed how quickly state rules are changing, and section 4 showed the same for GLP-1 programs. The FDA has warned sellers whose marketing implied compounded weight-loss drugs were "the same as an FDA-approved product when they are not" - FDA. For regenerative treatments it states plainly that "there are currently no FDA-approved exosome products" - FDA. Any service line resting on a product in that position is a regulatory bet, not a revenue line.

The plan's answer has two parts. Keep regulatory-risk lines out of the base case and show them as upside with their own risk note, and commit to a scheduled compliance review (quarterly is common) with your attorney and medical director, covering state law changes, product approvals and marketing claims. AmSpa's state-by-state legal updates are the most efficient way to keep that review current.

People and competition

The quiet risk in a small med spa is that patient loyalty attaches to the injector rather than the practice. If your lead injector leaves, a share of the neurotoxin book can leave too, and the cash flow behind the loan goes with it. The plan's answer is structural: patient records and communications held by the practice, memberships billed by the practice, documented treatment protocols, and a second clinician trained on your patients before you need one.

Competition is consolidating at the top while the base stays independent. Reuters reported in June 2026 that LaserAway, backed by Ares Management with around $150 million in EBITDA, was exploring a sale that could value it at more than $2 billion, and noted that KKR has invested in SkinSpirit and Leonard Green owns Milan Laser - Reuters via SRN News. SkinSpirit opened its 60th location at the end of 2025 - AmSpa. In 2026, 21 franchised locations that formerly operated as Ideal Image med spas were put up for sale - AmSpa. An independent spa will not win on price or convenience against a chain; the plan should say how it wins on continuity with one provider, specialization and the relationship that brings a patient back every three months.

11. Where med spas are heading, 2026 to 2028

A business plan covers five years, so it should say how you expect the market to change within them. The trends below are the ones with real evidence behind them rather than conference enthusiasm, and each has a concrete implication for the plan you are writing today.

The largest structural force is consolidation. A sell-side adviser writing on AmSpa's site in May 2026 estimated that more than 90% of med spas remain independently owned, put typical sale multiples at 3 to 6 times EBITDA for practices under $4 million in revenue, and said 2026 "could very well become a record-setting year" for deals - AmSpa. For a founder, that means the exit value of the practice depends on documented, transferable EBITDA, which is one more reason to build systems and records that belong to the practice rather than to any one person.

Prevention, regeneration and more toxin brands

Demand is shifting toward prevention and toward the young. Qsight reports neurotoxin's share of Gen Z non-surgical spending grew from 12% in 2021 to 20% in 2025 - Qsight. RealSelf's first-quarter 2026 trend report showed interest in Botox declining while interest grew in Sculptra and microneedling - AmSpa. The regenerative category is where the regulatory caution from section 10 applies most, because demand for treatments such as exosomes is running ahead of FDA approval.

The toxin shelf is also getting more crowded, which pushes price competition into your anchor product. Daxxify was approved in 2022 with a median duration of six months - Healio. Letybo's US label dates to 2024 - FDA. Galderma received a complete response letter for its toxin Relfydess in July 2026, citing manufacturing inspection and analytical method issues - Galderma. More brands mean more manufacturer promotions aimed at patients and more pressure on your per-unit price, so the plan's pricing section should state how you will respond rather than assume today's price holds for five years.

AI in the practice

AI adoption is moving faster among clinicians than among small-business tools. The AmSpa analysis cited in section 8 notes that more than 80% of physicians now use AI professionally - AmSpa. For a med spa, the near-term gains are administrative: answering inquiries around the clock, drafting chart notes for a clinician to approve, filling cancelled slots from a waitlist and assembling the owner's weekly numbers. None of those changes who may examine or treat a patient.

The implication for a five-year plan is to budget for administrative leverage rather than clinical replacement. A practice that answers every inquiry within minutes, reminds and rebooks every patient automatically and knows its utilization by provider each week can grow revenue without growing the front desk at the same rate. The clinical hour stays human and remains the constraint; the plan should treat it that way.

12. Putting the plan together

A med spa plan earns trust when every section points at the same few numbers. The legal structure determines who earns the medical revenue, the trade-area research justifies the visit ramp, the menu sets product cost and capital, the staffing plan sets payroll, the marketing plan sets the cost of new patients, and the financial model shows whether all of that covers the debt with room to spare. If you change one assumption, the others should move with it.

The order you write it in matters, because each step changes the next. Work through it in this sequence:

1. Confirm the structure with a healthcare attorney in your state: ownership, supervision, good faith exams and compensation
2. Profile the trade area with Census data and a priced competitor map, and set a visit ramp you can defend
3. Choose the launch menu using the scorecard above, with product cost, provider time and repeat cycle for each treatment
4. Build the model month by month, run the sensitivities, and test year-two coverage against 1.15 before you size the loan
5. Write the narrative last, starting with an executive summary that states the ask, the structure and the month you expect positive cash flow

The decision framework at the end is simple. If the base case passes the coverage test with a reserve you can actually raise, write the plan and apply. If it passes only in the optimistic scenarios, open smaller, lease more, or bring more equity until the base case works. If it fails even when visits run 20% above plan, the location or the menu is wrong, and the cheapest time to learn that is now, on paper.

Your business plan is also the first draft of how the practice will run. The same numbers that convince a lender (visits by provider, product cost per unit, rebooking rate, cost per new patient) are the ones you should watch every week after opening. A plan built that way does not end up in a drawer; it becomes the dashboard. For the non-medical parts of the setup, our AI for med spas overview covers the inquiry, booking, no-show and review systems in more detail.

This guide reflects regulations, prices and market data available as of October 2026. State laws, SBA rules, product prices and vendor terms change frequently, and nothing here is legal, tax or medical advice: confirm every structural and regulatory decision with a healthcare attorney and accountant licensed in your state before you rely on it.